NASDAQ:ARCT
Arcturus Therapeutics Holdings Inc. Stock News
$27.27
+0.750 (+2.83%)
At Close: May 03, 2024
Why Arcturus Therapeutics Stock Is Soaring Today
11:45am, Wednesday, 29'th Mar 2023
Arcturus beat expectations with its Q4 results. The company also provided an encouraging update on its pipeline programs.
Arcturus Therapeutics Holdings Inc. (ARCT) Q4 2022 Earnings Call Transcript
07:02pm, Tuesday, 28'th Mar 2023
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT ) Q4 2022 Earnings Conference Call March 28, 2023 4:30 PM ET Company Participants Neda Safarzadeh - IR Joseph Payne - President & CEO Andrew Sassine -
Arcturus Therapeutics (ARCT) Beats Q4 Earnings and Revenue Estimates
06:18pm, Tuesday, 28'th Mar 2023
Arcturus Therapeutics (ARCT) delivered earnings and revenue surprises of 332.80% and 19.14%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the sto
Arcturus' mRNA Platform: The Future Of Quick And Efficient Vaccine Delivery
04:01am, Wednesday, 01'st Feb 2023
Arcturus is revolutionizing biotechnology with its cutting-edge mRNA vaccines and delivery systems. They recently teamed up with CSL Seqirus, a leading player in the flu vaccine industry.
Arcturus Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
08:30am, Monday, 19'th Dec 2022
SAN DIEGO--( BUSINESS WIRE )--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global late-stage clinical messenger RNA medicines company focused on the develop
Arcturus Therapeutics Holdings Inc. (ARCT) Q3 2022 Earnings Call Transcript
09:11pm, Wednesday, 09'th Nov 2022
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT ) Q3 2022 Results Conference Call November 9, 2022 4:30 PM ET Company Participants Kyle Gutsadt - Investor Relations Joseph Payne - President and Chief
Arcturus Therapeutics (ARCT) Reports Q3 Loss, Tops Revenue Estimates
06:48pm, Wednesday, 09'th Nov 2022
Arcturus Therapeutics (ARCT) delivered earnings and revenue surprises of 33.83% and 281.97%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the st
Arcturus Therapeutics to Present at the Following Investor Conferences in November
05:00pm, Monday, 07'th Nov 2022
SAN DIEGO--(BUSINESS WIRE)--Arcturus Therapeutics Holdings Inc. (the “Company,” “Arcturus,” Nasdaq: ARCT), a global, late-stage clinical messenger RNA medicines company focused on the developm
Arcturus Therapeutics (ARCT) Surges 18.7%: Is This an Indication of Further Gains?
06:47am, Friday, 04'th Nov 2022
Arcturus Therapeutics (ARCT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strengt
Why Arcturus Therapeutics Stock Is Skyrocketing Today
12:00pm, Wednesday, 02'nd Nov 2022
Investors are applauding Arcturus' collaboration with CSL.
Why Is Arcturus Therapeutics (ARCT) Stock Up 30% Today?
11:06am, Wednesday, 02'nd Nov 2022
A strategic collaboration has today's traders talking about Arcturus Therapeutics (NASDAQ: ARCT ) and CSL (OTCMKTS: CSLLY ). Reportedly, the two companies will work together on mRNA technology for a w
Arcturus Therapeutics to Attend the Following Investor Conferences
06:00pm, Tuesday, 27'th Sep 2022
SAN DIEGO--(BUSINESS WIRE)--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global, late-stage messenger RNA medicines company focused on the development of in
7 Small-Cap Stocks to Buy on the Dip or You'll Be Kicking Yourself Later
12:28pm, Thursday, 22'nd Sep 2022
With several worrying developments domestically and internationally, many investors chose to rush for the exits, though a brave few may have opportunities in small-cap stocks to buy on the dip. Tether
Acrturus Therapeutics Holdings Inc. (ARCT) CEO Joseph Payne on Q2 2022 Results - Earnings Call Transcript
10:41pm, Tuesday, 09'th Aug 2022
Acrturus Therapeutics Holdings Inc. Q2 2022 Earnings Conference Call August 9, 2022 4:30 PM ET Company Participants Joseph Payne - President and Chief Executive Officer Andrew Sassine - Chief Financia
Arcturus Therapeutics (ARCT) Reports Q2 Loss, Tops Revenue Estimates
06:48pm, Tuesday, 09'th Aug 2022
Arcturus Therapeutics (ARCT) delivered earnings and revenue surprises of 55.43% and 714.09%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?